Category

Lundbeckfonden Ventures
Lund, Sweden, 18:00 CET, 16 August 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that its antibiotic-eluting product CERAMENT G has been approved by Health Canada. CERAMENT G is the first and only CE-marked gentamicin-eluting injectable ceramic bone graft substitute on the market. CERAMENT G sales have been...
August 14, 2018 Spero adds broad leadership and scientific expertise to its Board of Directors with appointment of John Pottage CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the appointment of John...
Palma, Spain and San Diego, USA, August 6th, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD). Most...
Lund, Sweden, 08:00 CET, 2 August 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, has signed an agreement with MTF Biologics, the world’s largest tissue bank, to extend and strengthen its US product offering. The agreement will give BONESUPPORT US rights to two forms of bone graft materials comprised...
New Haven, CT, July 19, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic conditions, announced today that it has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations....
Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONESUPPORT’s Chief Medical Officer, has been appointed to assume a broader role as Head of R&D, Medical and Clinical Affairs. Emil Billbäck, CEO of BONESUPPORT, commented: “We are pleased...
Cambridge, UK and Indianapolis, US – 9 July 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH) provides an unaudited operating update for the first half 2018 (six months ended 30 June 2018). Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea &...
Edinburgh – July 9th, 2018 – DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra colposcope used in cervical cancer screening, announces today the completion of an £18 million ($25 million) investment. Within the past year, DYSIS Medical has made significant strides and achieved key milestones including the launch of the latest generation device (DYSIS...
Lund, Sweden, 18:00 CET, July 4 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that are expected to take place at the end of 2018, when Håkan Johansson will replace Björn Westberg as the company’s CFO. Håkan Johansson is an experienced financial executive...
Cambridge, UK and Indianapolis, US – 2 July 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has secured a credit facility of up to $30 million with Hercules Technology...
1 2 3 40

Nyheder

Døren til et sukker-univers går op
17. august 2018
Unge danske talenter på unikt forskningsophold i Californien
7. august 2018
Derfor kan det hjælpe at give elektrochok 
17. juli 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge